Promising combo for rare breast cancer stalls after single patient
NCT ID NCT05198843
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study aimed to find a safe dose and see if combining dasatinib (a targeted cancer drug) with icosapent ethyl (an omega-3 fatty acid) could shrink tumors in people with a rare, aggressive form of breast cancer that had spread. Only one person enrolled before the study was stopped early, so we don't have enough information to know if the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.